Shanghai Junshi Bioscience Co., Ltd.

This trial is testing whether toripalimab, an immunotherapy drug, can help prevent liver cancer from returning after surgery. Participants are people with hepatocellular carcinoma who have a high risk of recurrence despite having had the tumor completely removed. Half will receiv…

This early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…

This clinical trial is testing whether a new investigational drug called JS207, which targets two proteins involved in tumor growth (PD-1 and VEGF), can be safely combined with standard chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The st…

This phase 2 trial is testing whether adding an experimental bispecific antibody called JS207—which targets both PD-1 and VEGF—to standard platinum-based chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer (NSCLC). Participants will receive t…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy helps people with advanced bladder cancer that has not been treated before. Participants have a type of bladder cancer that has spread or cannot be removed by surgery and shows a protein c…

This phase 3 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy after stomach cancer surgery can help prevent the cancer from coming back. About 878 patients who had their stomach cancer completely removed will receive either toripalimab plus c…

This study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…

This Phase 3 trial tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 participants will receive either the combination or a placebo plus lenvatinib. The study is double…

This early-stage trial is testing a new drug called JS207 in about 98 people with advanced cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also loo…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer. About 663 participants will receive either toripalimab plus chemo or a placebo plus chemo. The goal…

This early-stage study is testing an experimental drug called JS203 in about 104 people with relapsed or refractory B-cell non-Hodgkin's lymphoma, a type of blood cancer. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinkin…